The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 12, 2021
Filed:
Nov. 01, 2016
Applicant:
Genase Therapeutics B.v., Oss, NL;
Inventors:
Sonia Lain, Stockholm, SE;
Catherine Drummond, Memphis, TN (US);
Ingeborg Van Leeuwen, Stockholm, SE;
Martin Haraldsson, Täby, SE;
Lars Johansson, Bromma, SE;
Lars Sandberg, Enskede, SE;
Ulrika Yngve, Uppsala, SE;
Assignee:
Genase Therapeutics B.V., Oss, NL;
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/12 (2006.01); A61P 35/00 (2006.01); A61P 31/14 (2006.01); A61K 45/06 (2006.01); C07D 417/12 (2006.01); A61K 31/427 (2006.01); C07D 413/12 (2006.01); A61K 31/422 (2006.01); C07D 403/12 (2006.01); A61K 31/497 (2006.01); C07D 405/12 (2006.01); A61K 31/416 (2006.01); C07D 409/12 (2006.01); C07D 471/04 (2006.01); A61K 31/437 (2006.01); A61K 31/5377 (2006.01); A61K 31/506 (2006.01); A61K 31/4439 (2006.01); C07D 413/14 (2006.01); A61K 31/4709 (2006.01); A61K 31/423 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01); A61K 31/416 (2013.01); A61K 31/422 (2013.01); A61K 31/423 (2013.01); A61K 31/427 (2013.01); A61K 31/437 (2013.01); A61K 31/4439 (2013.01); A61K 31/4709 (2013.01); A61K 31/497 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01); A61P 35/00 (2018.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01);
Abstract
There is herein provided a compound of formula I (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer and/or the treatment or prevention of a viral infection, wherein A, A, L, R, Rand n have meanings as provided in the description.